Paris
Paris
Paris is a plant traditionally associated with various herbal remedies but lacks specific traditional uses documented. Scientific evidence regarding its efficacy is limited; studies suggest that misclassification between clinical judgment and formal criteria for primary biliary cholangitis (PBC) occurs in approximately 20% of cases, potentially impacting treatment decisions. However, the broader scientific literature does not provide robust evidence supporting any particular therapeutic use. Safety concerns are minimal, with no major issues recorded, and there are currently no known drug interactions reported.
- Best evidence
- D
- Cautions
- —
Informational only. Traditional use does not mean proven effectiveness. Evidence and safety vary — check the cited sources.
What the science says
- Misclassification between clinical judgment and formal Paris II criteria occurs in about 20% of PBC patients, potentially affecting treatment decisions.
- The review summarizes current practices and materials for managing equine cheek tooth alveoli post-extraction but does not establish standardized protocols.
- The study found that using cefotaxime instead of ceftriaxone in Paris hospitals would increase carbon emissions, waste production, and costs.
- Children with MARS1-related pulmonary alveolar proteinosis show borderline to mild intellectual disability and significant deficits in adaptive behavior, despite methionine supplementation.
- The effectiveness of healthcare quality systems depends more on leadership commitment and workforce engagement than formal adoption alone, with mixed evidence for direct impacts on patient outcomes.
- SSM measurements during normal breathing showed better diagnostic accuracy for predicting oesophageal varices compared to breath-hold measurements.
Frequently asked questions
What is Paris?
Paris (Paris) is a plant documented in FolkKB's traditional-medicine reference, drawn from sourced literature and cross-checked against the evidence.
What does the scientific evidence say about Paris?
6 sourced findings are recorded for Paris; the strongest carries evidence grade D. For example: Misclassification between clinical judgment and formal Paris II criteria occurs in about 20% of PBC patients, potentially affecting treatment decisions.
How strong is the evidence for Paris?
The strongest finding for Paris carries evidence grade D — preliminary or traditional. Grades run A (strongest) to D (preliminary or traditional).
Is Paris safe? What are the side effects?
No major safety issues are recorded for Paris in our sources, but the data may be incomplete. Consult a qualified professional before use.
Does Paris interact with medications?
No drug interactions are recorded for Paris in our sources. This does not rule them out — check with a pharmacist.
What are the common names of Paris?
Paris is also known as: Вороний глаз, Parisette.
Is Paris a proven treatment?
No. FolkKB is informational only. Traditional use and early findings are not proof of efficacy or safety — consult a qualified professional and never self-treat.
Sources
- T2 The environmental impacts and costs of cefotaxime versus ceftriaxone: An example drawn from Paris hospitals. literature abstract metadata
- T2 Management of Equine Post-Extraction Cheek Tooth Alveoli: Application of Alveolar Plugs. literature abstract metadata
- T2 Healthcare Quality Systems: International Frameworks, Evaluation and Improvement Strategies. literature abstract metadata
- T2 Misclassification of UDCA treatment response in patients with primary biliary cholangitis (PBC) in the real-world setting. literature abstract metadata
- T2 Neurodevelopmental Profile of Children With MARS1-Related Pulmonary Alveolar Proteinosis: A Cohort Study. literature abstract metadata
- T2 Impact of Breath Holding on Spleen Stiffness Measured by 100 Hz Vibration Controlled Transient Elastography. literature abstract metadata